Short answer · Medically reviewed summary · Last updated: 2023-07-13
Ornithine Transcarbamylase Deficiency (OTCD) is a rare genetic disorder that affects the urea cycle, a metabolic pathway responsible for removing ammonia from the body. It is an X-linked disorder, meaning it primarily affects males, although some females can also be affected.
What is the prevalence of Ornithine Transcarbamylase Deficiency?
Prevalence of Ornithine Transcarbamylase Deficiency: how many people are affected worldwide, differences by sex and region, with sources.
Ornithine Transcarbamylase Deficiency (OTCD) is a rare genetic disorder that affects the urea cycle, a metabolic pathway responsible for removing ammonia from the body. It is an X-linked disorder, meaning it primarily affects males, although some females can also be affected.
The prevalence of OTCD varies among different populations. In the general population, it is estimated to occur in approximately 1 in 80,000 to 1 in 100,000 live births. However, the prevalence may be higher in certain ethnic groups, such as individuals of Middle Eastern or North African descent, where it can occur in 1 in 3,000 to 1 in 5,000 live births.
OTCD can present at any age, from the neonatal period to adulthood, with varying degrees of severity. Severe cases often manifest in the first few days of life, leading to life-threatening hyperammonemia. Mild or late-onset cases may present later in childhood or even adulthood, with symptoms such as recurrent vomiting, lethargy, behavioral changes, and neurological impairment.
Early diagnosis and treatment are crucial for managing OTCD. Genetic counseling and carrier testing are recommended for families with a history of the disorder. With appropriate medical interventions, including dietary modifications, medications, and liver transplantation in severe cases, individuals with OTCD can lead relatively normal lives.
